KRAS and acute myeloid leukemia: Mutations in Dnamt3a or loss of Dnamt3a synergize with other alterations such as Kras (G12D/+) [123], FLT3-ITD [22,23], Npm1cA/+ [134], Bcor−/− [135] and IDH2 neomorphic mutations [133] to develop AML in mice (Table 2; Supplementary Figure S3).